Literature DB >> 2129237

[Anti-HLA antibodies (Ab1) and anti-idiotypic antibodies (Ab2) directed against Anti-HLA Ab1 in various preparations of polyspecific immunoglobulins for intravenous use].

S Barocci1, D Fenoglio, A Leprini, A Nocera.   

Abstract

In this study, different intravenous immunoglobulin infusions (I.V. Ig.), were analyzed for the presence of either anti-HLA antibodies (Ab1) or anti-idiotypic antibodies (Ab2) directed against Ab1 anti-HLA. No evidence of either antibody types was found in tested I.V. Ig. preparations. Because of the absence of Ab1 anti-HLA, prophylactic and/or therapeutic use of I.V. Ig. appears safe in patients waiting for organ graft or in transplanted patients. The lack of Ab2 anti-Ab1 anti-HLA makes worthless the utilization of such preparations for neutralization of Ab1 present in highly sensitized dialysis patients or suppression of their production in transplanted patients in contrast with the previous reports suggesting this possibility.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2129237

Source DB:  PubMed          Journal:  Boll Soc Ital Biol Sper        ISSN: 0037-8771


  2 in total

1.  Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg.

Authors:  D Zhu; M H Ravindranath; P I Terasaki; T Miyazaki; T Pham; V Jucaud
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

Review 2.  HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs.

Authors:  Mepur H Ravindranath
Journal:  J Immunol Res       Date:  2017-05-28       Impact factor: 4.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.